TY - JOUR
T1 - Prognostic factors in node-negative breast cancer patients: 7 years follow-up
AU - Hillen, H.F.P.
AU - Blijham, G.H.
AU - von Meyenfeldt, M.F.
AU - Volovics, L.
AU - Schutte, B.
AU - Schouten, L.J.
AU - Jager, J.J.
AU - de Jong, J.
AU - Schouten, H.C.
AU - Hupperets, P.S.G.J.
PY - 1996/1/1
Y1 - 1996/1/1
N2 - An immunohistochemical determination of the growth fraction (gf) with the ki-67 monoclonal antibody has been performed in a prospective series of 140 patients with primary operable breast carcinoma. Gf ranged from 0% to 43% ki-67 stained cells with a median value of 8%. High gf (> 8%) was significantly associated with axillary node involvement (p = 0.006), aneuploidy (p = 0.008), histologic grade (p = 0.03), and s-phase fraction > 5% determined by flow cytometry (p = 0.01). After a median follow-up of 6 years, the univariate analysis did not show significant correlation between high gf and worse relapse-free survival (p = 0.10) or shorter overall survival. However, a multivariate analysis on relapse-free survival, performed in 127 comparable patients, showed that gf was an independent predictive factor (p = 0.03) together with nodal status (p = 0.00001), age under 45 years (p = 0.0008), and chemotherapy (0.006). In node negative patients, gf was still an independent prognostic indicator (p = 0.002) together with age under 45 years (p = 0.0003). Tumor proliferative activity evaluated by the monoclonal antibody ki-67 appears to be an effective indicator of prognosis in breast cancer and could be of assistance in the decision making of adjuvant therapy in node negative patients.
AB - An immunohistochemical determination of the growth fraction (gf) with the ki-67 monoclonal antibody has been performed in a prospective series of 140 patients with primary operable breast carcinoma. Gf ranged from 0% to 43% ki-67 stained cells with a median value of 8%. High gf (> 8%) was significantly associated with axillary node involvement (p = 0.006), aneuploidy (p = 0.008), histologic grade (p = 0.03), and s-phase fraction > 5% determined by flow cytometry (p = 0.01). After a median follow-up of 6 years, the univariate analysis did not show significant correlation between high gf and worse relapse-free survival (p = 0.10) or shorter overall survival. However, a multivariate analysis on relapse-free survival, performed in 127 comparable patients, showed that gf was an independent predictive factor (p = 0.03) together with nodal status (p = 0.00001), age under 45 years (p = 0.0008), and chemotherapy (0.006). In node negative patients, gf was still an independent prognostic indicator (p = 0.002) together with age under 45 years (p = 0.0003). Tumor proliferative activity evaluated by the monoclonal antibody ki-67 appears to be an effective indicator of prognosis in breast cancer and could be of assistance in the decision making of adjuvant therapy in node negative patients.
U2 - 10.1007/BF01806632
DO - 10.1007/BF01806632
M3 - Article
C2 - 8750528
SN - 0167-6806
VL - 37
SP - 57
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - S
ER -